(NY Times) Shares of biotech firm Cassava Sciences plunged 24% in premarket on Tuesday after more researchers faulted its trial results for the experimental Alzheimer drug. Cassava claimed, last summer,…
(WSJ) US Food and Drug Administration has declined a petition filed by short-sellers seeking to stop the clinical trials of Cassava Sciences Inc. Alzheimer drug. Two short-sellers had alleged that…
(RetractionWatch) Shares of Cassava Sciences Inc. rose more than 28% on Tuesday after the Journal of Neuroscience said it finds no evidence of manipulation of data for its experimental drug…
(WSJ) Shares of Cassava Sciences Inc. fell more than 23% on news that the SEC was examining whether the company manipulated data on their Alzheimer drug. The investigation by the…
(Cassava Sciences) Shares of Cassava Sciences were up more than 18% in premarket after its drug candidate simufilam showed breakthrough for mild to moderate forms of Alzheimer disease. In an…